PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Teriparatide — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Teriparatide is recombinant human parathyroid hormone (1-34), an anabolic therapy for severe osteoporosis rather than an inhibitor of bone resorption. · pmid:15769903

History

In the VERO trial of 1,360 postmenopausal women with severe osteoporosis, new vertebral fractures occurred in 5.4% on teriparatide against 12.0% on risedronate over 24 months. · pmid:29129436

Identity

PubChem CID 16133850: Teriparatide, C181H291N55O51S2, 4118 g/mol. · pubchem:16133850

CAS registry number 52232-67-4. · pubchem:16133850

Where the evidence actually sits

Established100%

Proportion of the 2 claims about Teriparatide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. (2005) · establishedEffects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. (2018) · established20052018

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Teriparatide yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. · pmid 15769903 · 2005
    • Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. · pmid 29129436 · 2018
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.